Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MST-188 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Study Drug | EXPERIMENTAL | MST-188 |
| MST-188 | EXPERIMENTAL | MST-188 injection administered as a continuous infusion 100 mg/kg for 1 hour followed by 30 mg/kg/hr for up to 48 hours. |
| Saline | PLACEBO_COMPARATOR | Saline administered as a continuous infusion for up to 49 hours |
| Name | Type | Description |
|---|---|---|
| MST-188 | DRUG | Intravenous administration as 100 mg/kg for 1 hour followed by 30 mg/kg/hour for up to 48 hours. |
| Saline | DRUG | - |
Inclusion Criteria: * Completed participation in study MST-188-01 (EPIC study) * Subject age 4 through 65 years * Subject is experiencing acute pain typical of VOC and requires treatment with parenteral opioid analgesia * Subject requires hospitalization Exclusion Criteria: * Subject has acute ch...
MST-188 is an investigational small molecule being developed for the treatment of vaso-occlusive crisis in sickle cell disease. It is a purified form of poloxamer 188, a surfactant that may help restore blood flow by reducing red blood cell adhesion and improving microvascular perfusion.
MST-188 is being developed by Savara, Inc., a biopharmaceutical company focused on rare respiratory diseases. Savara is publicly traded on the NASDAQ under the ticker symbol SVRA.
MST-188 has completed Phase 3 clinical trials for vaso-occlusive crisis in sickle cell disease. The drug is investigational and has not been approved by the FDA. It remains in clinical development, with completed trials evaluating its safety and efficacy.
MST-188 has been studied in two Phase 3 trials. The EPIC trial (NCT01737814) enrolled 388 participants with vaso-occlusive crisis across multiple countries, including the United States, Belgium, and Brazil. A second trial (NCT02449616) evaluated repeat administration in 16 participants with sickle cell disease in the United States.
MST-188 is a purified form of poloxamer 188, a copolymer surfactant. It is being developed specifically for vaso-occlusive crisis in sickle cell disease, where it aims to improve blood flow by reducing red blood cell adhesion and inflammation.